New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.

Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.

A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program ...

Less than a month after taking over as interim CEO of Legend Biotech, Alan Bash is signaling continuity rather than a reset. Bash joined Legend in October 2024 to lead its Carvykti business after two ...

Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial ...

What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a ...

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...

Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, real-world ...